Study guide

Depression assessment and treatment

AMC CAT MCQ Examination AMC Part 1

Track your progress as you read

Finished sections get a check mark.

1 Acute Coronary Syndromes & ECG Localization

ACS recognition and ECG localisation Reperfusion and infarction complications

2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias

Heart failure assessment and treatment Arrhythmias and conduction emergencies

3 Systemic Hypertension & Peripheral Vascular Disease

Blood pressure and cardiovascular risk Secondary hypertension and arterial disease

4 Valvular Heart Disease, Infective Endocarditis & Pericarditis

Aortic and mitral valve disease Endocarditis and pericardial emergencies

5 Asthma & COPD Acute Flares and Maintenance

Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations

6 Pneumonia, pleural disease and respiratory failure

Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis

7 GI bleeding, bowel inflammation and malabsorption

GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS

8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis

Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance

9 Diabetes, thyroid and adrenal disease

Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease

10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies

AKI and chronic kidney disease Potassium and sodium emergencies

11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment

Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care

12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis

Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia

13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology

Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms

14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis

Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment

15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries

Trauma primary survey and adjuncts Chest trauma and immediate threats

16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance

Head injury, imaging and haemorrhage Herniation and spinal cord injury

17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome

Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury

18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care

Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus

19 Aortic Aneurysms & Acute Arterial Limb Ischaemia

Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia

20 Urological Emergencies, Testicular Torsion & Haematuria Investigation

Retention, stones and obstructed infection Scrotal pain and haematuria

21 Preoperative Risk Stratification & Postoperative Surgical Complications

Preoperative assessment and medicines Postoperative complications and prevention

22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening

Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons

23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy

Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding

24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies

Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth

25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis

Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care

26 Contraception, Emergency Contraception & Pregnancy Termination

Contraceptive choice and missed pills Emergency contraception and abortion

27 Australian Cervical Screening Program & Gynaecological Malignancies

Cervical screening and cervical cancer Endometrial and ovarian cancer

28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice

Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening

29 Developmental Milestones, Growth Charts & Failure to Thrive

Developmental milestones Regression, autism and support Faltering growth and developmental comparisons

30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions

Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons

31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis

Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis

32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease

Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up

33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury

Pyloric stenosis Intussusception and dehydration Child protection and injury assessment

34 The Mental State Examination & Suicide Risk Stratification

Mental state examination and psychotic symptoms Suicide formulation and mental health law

35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers

Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT

36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder

Anxiety, panic and agoraphobia OCD and trauma-related disorders

37 Schizophrenia, Acute Psychosis & Antipsychotic Management

Psychosis assessment and antipsychotics Clozapine and severe adverse effects

38 Substance Use Disorders & Acute Withdrawal Syndromes

Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants

39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry

Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry

40 Medicare, PBS, AHPRA & Good Medical Practice Framework

Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications

41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment

Consent, material risks and young people Capacity, refusal and substitute decisions

42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications

Privacy, disclosure and child reporting Driving fitness and threat disclosure

43 First Nations health and preventive care

First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention

44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases

Epidemiology, calculations, bias and surveillance

45 Neurological presentations

Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness

46 Musculoskeletal pain

Back, neck, bone and soft tissue pain

47 Eye presentations

Altered vision and retinal disease Red eye, ocular injury and discharge

48 Ear, nose, throat and oral health

Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis

49 Skin, hair and nails

Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities

50 Breast health and feeding

Breast lumps, discharge and breastfeeding problems

51 Sexual and reproductive presentations

Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction

52 Palliative care and carers

The dying patient, symptoms and carers

53 Eating disorders and personality care

Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care

54 Sleep presentations

Insomnia, snoring and daytime sleepiness

55 Poisoning, resuscitation and environmental emergencies

Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning

56 Communication, rights and professional practice

Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health

57 Genetics, research and donation

Genetic testing, research and organ donation

58 Travel, fever and outbreaks

Fever, travellers and outbreak response

Depression assessment and treatment

Key Takeaways Explain This Topic AI

Ask about previous mania or hypomania before treating apparent unipolar depression.

SSRIs require monitoring for adverse effects and clinical response.

Psychological therapy is an important treatment option.

Last updated: October 2026

Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers

Mood disorders represent the leading cause of non-fatal disease burden in Australian clinical medicine. Under guidelines published by the Royal Australian and New Zealand College of Psychiatrists (RANZCP), medical practitioners must master diagnostic phenotyping, pharmacological titration, adverse effect surveillance, and somatic interventions across the depressive and bipolar spectrum.

Major Depressive Disorder (MDD)

Major Depressive Disorder is a severe, recurring psychiatric illness characterized by persistent disturbances in affect, cognitive processing, vegetative neurobiology, and interpersonal functioning.

Diagnostic Criteria (DSM-5)

A definitive diagnosis of Major Depressive Disorder requires at least 5 of the following 9 symptoms present during the same 2-week period , representing a clear change from prior baseline functioning. Crucially, at least one of the symptoms must be either (1) depressed mood or (2) loss of interest or pleasure (anhedonia) .

Clinical Phenotypes and Subtypes

Melancholic / Biological Depression : Characterized by profound vegetative disturbance: anhedonia that is unreactive to positive events, a distinct quality of depressed mood (felt as physical anguish or emptiness), diurnal variation (regularly worse in the early morning), terminal insomnia (awakening at least 2 hours before normal waking time), marked psychomotor retardation or agitation, significant anorexia, and excessive guilt. Highly responsive to biological therapies (SSRIs, SNRIs, tricyclics, ECT).

Atypical Depression : Characterized by preserved mood reactivity (mood brightens transiently in response to positive stimuli), leaden paralysis (heavy, lead-like sensation in arms or legs), reversed vegetative signs (hyperphagia with carbohydrate craving, hypersomnia), and long-standing interpersonal rejection sensitivity.

Psychotic Depression : Depressive episodes complicated by hallucinations or delusions. Psychotic themes are usually mood-congruent (delusions of worthlessness, guilt, financial ruin, severe incurable somatic illness, or Cotard nihilistic delusions). Psychotic depression requires combination therapy with an antidepressant plus an atypical antipsychotic, or urgent Electroconvulsive Therapy (ECT) , as antidepressant monotherapy has unacceptably high failure rates.

Assessment and Screening Tools in Australian Practice

Kessler Psychological Distress Scale (K10) : A 10-item questionnaire measuring psychological distress over the past 4 weeks. Heavily embedded in the Australian Medicare system for initiating and reviewing General Practice Mental Health Treatment Plans (MHTP under Better Access).

Patient Health Questionnaire-9 (PHQ-9) : A 9-item scale directly mapping onto the 9 DSM-5 criteria, utilized for grading depression severity (mild: 5–9, moderate: 10–14, moderately severe: 15–19, severe: 20–27) and monitoring longitudinal treatment response.

Pharmacotherapy of Depression: Assessment and treatment principles

For mild depression, low-intensity psychological strategies (structured physical exercise, sleep hygiene, online CBT such as MoodGYM or MindSpot) are first-line. For moderate to severe MDD, pharmacotherapy combined with evidence-based psychotherapy (Cognitive Behavioural Therapy or Interpersonal Psychotherapy) is the gold standard.

First-Line Antidepressants: SSRIs & SNRIs

Selective Serotonin Reuptake Inhibitors (SSRIs) :

First-line choices: Sertraline ( 50 to 200 mg 50\text{ to }200\text{ mg} 50 to 200 mg daily) and Escitalopram ( 10 to 20 mg 10\text{ to }20\text{ mg} 10 to 20 mg daily).

Antidepressant choice: Sertraline is often suitable in cardiac disease or breastfeeding, but no agent is universally safest for every patient. Review indication, interactions, prior response and perinatal advice.

Escitalopram is highly selective but carries a dose-dependent risk of QTc prolongation ; maximum dose is capped at 20 mg 20\text{ mg} 20 mg daily ( 10 mg 10\text{ mg} 10 mg daily in adults aged ≥ 65 years \ge 65\text{ years} ≥ 65 years ).

Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs) :

Agents: Venlafaxine ( 75 to 225 mg 75\text{ to }225\text{ mg} 75 to 225 mg daily) and Duloxetine ( 30 to 60 mg 30\text{ to }60\text{ mg} 30 to 60 mg daily).

Particularly effective in melancholic depression, severe refractory depression, and depression comorbid with chronic neuropathic pain.

Noradrenergic activation can cause dose-dependent hypertension; baseline and regular blood pressure monitoring is mandatory.

Key Adverse Effects & Clinical Management

Gastrointestinal Symptoms : Nausea, loose stools, and dyspepsia occur early due to stimulation of peripheral 5-HT3 receptors; usually self-limiting within 7 to 14 days.

Sexual Dysfunction : Reduced libido, erectile dysfunction, delayed ejaculation, and anorgasmia occur in up to 30% to 50% of patients and typically persist throughout treatment. Management includes dose reduction, switching to non-serotonergic agents (such as mirtazapine or agomelatine), or adding a PDE-5 inhibitor.

Hyponatraemia / SIADH : Caused by inappropriate ADH release, particularly in elderly patients, those on concurrent thiazide diuretics, or those with low baseline sodium. Serum electrolytes must be checked at baseline and 2 to 4 weeks after initiation in older adults.

Bleeding Risk : Platelets take up serotonin from plasma to facilitate aggregation. SSRIs deplete platelet serotonin, doubling the risk of upper gastrointestinal bleeding. Co-prescription with NSAIDs, aspirin, or oral anticoagulants requires gastroprotection with a proton pump inhibitor.

Black-Box Suicidality Warning : In children, adolescents, and young adults under 25 years of age, initiation of SSRIs/SNRIs can induce a paradoxical transient surge in agitation, akathisia, and suicidal thoughts during the first 1 to 2 weeks before therapeutic mood elevation occurs. Close weekly clinical review is mandatory during early titration.

Therapeutic Trial Duration & Discontinuation

Adequate Trial : A minimum of 4 to 6 weeks at an established therapeutic dose is required to judge clinical efficacy. If no improvement is observed at 4 weeks, titrate to the maximum tolerated dose or switch to another first-line class.

Maintenance Duration : Following complete symptomatic remission, antidepressant therapy must continue for at least 6 to 12 months for a first depressive episode to prevent relapse. For recurrent depression ( ≥ 2 \ge 2 ≥ 2 or 3 lifetime episodes), maintenance therapy is recommended for at least 2 to 5 years , or indefinitely.

Stopping antidepressants: Taper collaboratively according to drug, duration, dose and withdrawal symptoms. Some patients need a much slower taper over months. Distinguish withdrawal from relapse and adjust the plan rather than enforcing a universal four-to-eight-week schedule.

Primary references (checked 7 October 2026): EXTRIP lithium recommendations .